Clinically relevant, patient-derived pancreatic cancer organoids that faithfully recapitulate the histological architecture, genomic landscape, and therapeutic response profiles of pancreatic ductal adenocarcinoma (PDAC).
- Overview
- Details
- Advantages
- FAQs
Overview
Pancreatic cancer remains one of the most lethal malignancies worldwide, with pancreatic ductal adenocarcinoma (PDAC) accounting for approximately 90% of cases. Late diagnosis, aggressive local invasion, early metastasis, and profound desmoplasia collectively contribute to its dismal prognosis and limited therapeutic options.
Genomically, PDAC is defined by recurrent alterations in KRAS, TP53, CDKN2A, and SMAD4, alongside dysregulation of DNA damage repair and epigenetic pathways. This complex molecular landscape drives tumor heterogeneity and underpins intrinsic and acquired therapy resistance.
Traditional 2D cell cultures fail to capture the three-dimensional architecture, stromal crosstalk, and functional diversity of PDAC. In contrast, patient-derived organoids (PDOs) preserve the structural and molecular fidelity of primary tumors, offering a physiologically relevant platform for translational oncology.
Key Pathological Features Recapitulated by Pancreatic Cancer Organoids
- Histopathological fidelity to pancreatic ductal adenocarcinoma (PDAC)
- Recurrent oncogenic mutations in KRAS, TP53, CDKN2A, and SMAD4
- Desmoplastic stroma and poorly differentiated tumor phenotypes
- Expression of canonical PDAC markers including CK19, CA19-9, EPCAM, and SOX9
- Enrichment of cancer stem cell–like populations linked to recurrence
- High inter- and intra-tumoral heterogeneity
- Resistance profiles to standard chemotherapies and targeted agents
- Invasive phenotypes associated with metastatic potential
These attributes position pancreatic cancer organoids as a powerful, clinically aligned model for studying disease progression and evaluating novel therapeutic strategies.
Fig. 1. Generation and application of patient-derived pancreatic cancer organoids (Bengtsson A, Andersson R,
et al., 2021).
Our Pancreatic Cancer Organoids
Our pancreatic cancer organoids are established from primary tumor specimens and cultured under rigorously optimized conditions to maintain disease-relevant morphology, genomic integrity, and functional phenotypes.
Disease-Relevant Features
- Authentic patient-derived models reflecting real-world PDAC biology
- Preserved ductal architecture mirroring native tumor histology
- Molecular heterogeneity driven by key oncogenic alterations
- Stromal signaling context relevant to tumor–microenvironment interactions
Characterization & Quality Assurance
Every pancreatic cancer organoid line undergoes comprehensive validation to ensure identity, stability, and translational relevance.
- Genomic profiling: Targeted sequencing of PDAC-associated alterations including KRAS, TP53, CDKN2A, and SMAD4
- Biomarker validation: Immunodetection of CK19, CA19-9, EPCAM, SOX9, and lineage-specific markers
- Morphological assessment: 3D structural evaluation consistent with PDAC histology
- Functional phenotyping: Proliferation and drug response profiling under defined assay conditions
- Batch consistency: Post-thaw viability ≥85%, verified identity, minimal lot-to-lot variability, mycoplasma-negative certification
Applications
Our pancreatic cancer organoids support a broad spectrum of preclinical and translational research applications:
- Disease Mechanisms: Elucidation of PDAC initiation, progression, and metastatic cascades.
- Drug Discovery & Screening: Profiling of chemotherapeutics, targeted agents, and combination regimens.
- Precision Oncology: Patient-specific therapeutic response modeling to guide individualized strategies.
- Resistance Research: Investigation of intrinsic and adaptive resistance mechanisms.
- Tumor Microenvironment Studies: Analysis of stromal signaling and immune–tumor interactions.
Why Choose Our Pancreatic Cancer Organoids
- Clinically Anchored: Derived from authentic patient tumors to reflect real-world PDAC biology
- Biological Fidelity: Preservation of aggressive phenotypes and molecular complexity
- Workflow Ready: Cryopreserved format enables immediate experimental deployment
- Rigorous QC: Standardized validation ensures reproducibility and reliability
- Translational Versatility: Compatible with high-throughput screening and mechanistic studies
FAQs
Q: What pancreatic cancer subtypes are represented?
The majority of our models are pancreatic ductal adenocarcinoma (PDAC), the most prevalent and aggressive subtype. Other rare subtypes can be provided upon request.
Q: Which driver mutations are typically present?
Most models harbor canonical PDAC alterations such as KRAS, TP53, CDKN2A, and SMAD4, with mutation spectra reflective of individual patient tumors.
Q: What research applications are supported?
Applications span drug screening, biomarker discovery, transcriptomic and proteomic profiling, pathway analysis, and resistance mechanism studies.
Q: Can custom pancreatic cancer organoids be developed?
Yes. We offer custom organoid development services tailored to specific genetic backgrounds, therapeutic targets, or experimental objectives.
Advance pancreatic cancer research with physiologically faithful, patient-derived organoid models designed for translational impact.
Contact us to obtain detailed characterization reports, pricing, or customized organoid solutions aligned with your scientific goals.
Online Inquiry